奥沙拉嗪联合地塞米松保留灌肠治疗溃疡性结肠炎的疗效评价

目的]评价奥沙拉嗪联合地塞米松保留灌肠治疗溃疡性结肠炎(ulcerative colitis,UC)的疗效及安全性.方法]50例UC患者随机分为观察组(26例,采用奥沙拉嗪联合地塞米松保留灌肠)、对照组(24例,采用柳氮磺嘧啶联合地塞米松保留灌肠),比较2组治疗前及治疗1个月、2个月后患者疾病活动指数(disease activity index,DAI),治疗2个月后总有效率及不良反应发生情况.结果]2组患者治疗前DAI差异无统计学意义(P＞0.05)；治疗1个月后,2组患者DAI均较治疗前降低(P＜0.05),而2组间比较差异无统计学意义(P＞0.05)；治疗2个月后,2组DAI均较治疗前下降显著(P＜0.01),观察组优于对照组,差异有统计学意义(P＜0.05).治疗2个月后,观察组总有效率为92.3％,对照组为75.0％,2组比较差异有统计学意义(P＜0.05).结论]奥沙拉嗪联合地塞米松保留灌肠治疗UC患者安全有效,值得临床推广.

Evaluation of the efficacy of olsalazine combined with dexamethasone in treating patients with ulcerative colitis

Objective]To evaluate the efficacy and safety of retention enema of olsalazine in combination with dexamethasone in the treatment of ulcerative colitis.Methods]Fifty cases of ulcerative colitis patients were divided into observation group and control group randomly,and twenty-six persons in observation group treated with olsalazine in combination with dexamethasone retention enema,twenty-four persons in control group treated with sulfasalazine pyrimidine in combination with dexamethasone retention enema.The disease activity index,total efficiency rates and side effects of two groups were compared one and two months later.Results]No significant difference of the DAI index was found between the two groups before treatment(P> 0.05).After one-month-treatment,the DAI index of two groups was significantly lower than that before treatment respectively(P<0.05),and the difference between the two groups was not significant(P>0.05).Two months later,the DAI indexes were decreased significantly compared with those before treatment(P<0.01),and the observation group was remarkably lower than the treatment group(P<0.05).Conclusion]Olsalazine in combination with dexamethasone retention enema is a safe and effective treatment for patients with ulcerative colitis,which is worthy of clinical application.